Xenon Pharmaceuticals Inc. (XENE) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Net income	-163.7	-147.4	-125.4	-113.5	-91.8	-82.3	-77.9	-65.2
Depreciation and amortization	1.8	1.6	1.6	1.4	1.2	1.1	0.9	0.8
Stock-based compensation				-8.8				-4.1
Deferred taxes				-0.2				0.2
Change in working capital [+]	43.1	43.3	38.1	26.5	24.8	25.5	24.3	9.3
Accounts receivable				-0.2				0.8
Other current assets				-0.4				0.0
Other	43.8	44.0	38.8	27.2	23.8	21.7	24.3	8.5
Other operating activities	-3.0	-2.9	-3.8	8.2	-0.5	-9.6	-16.8	-3.1
Cash from operations	-130.8	-114.4	-98.4	-86.4	-71.0	-67.2	-69.5	-61.9

Capital expenditures	8.0	6.4	4.4	3.2	4.1	2.7	2.1	6.0
Purchases of property and equipment	8.0	6.4	4.4	3.2	4.1	2.7	2.1	6.0
Purchases of short-term investments, net	868.5	778.9	739.6	882.0	576.7	513.1	389.5	574.7
Purchases of short-term investments	963.3	873.7	834.4	976.9	653.4	559.1	389.5	574.7
Sales of short-term investments				-94.8				0.0
Other cash from investing	-1,050.4	-985.8	-1,040.0	-1,382.3	-828.3	-756.4	-638.3	-568.9
Cash from investing	-173.9	-200.5	-296.0	-497.1	-247.4	-240.6	-246.8	11.9

Issuance of common stock, net					0.0	7.9
Option exercises			0.7	0.7			0.3	0.3
Other cash from financing			279.2	603.1	606.5		447.8	123.9
Cash from financing	0.7	270.6	278.5	602.4	606.5	336.7	447.5	123.6

Free cash flow	-122.8	-108.0	-94.0	-83.2	-66.9	-64.6	-67.5	-55.9
Per share (diluted)	($1.91)	($1.74)	($1.59)	($1.51)	($1.36)	($1.41)	($1.64)	($1.44)